SCC237

YUMM4.1 Mouse Melanoma Cell Line

Mouse

• 别名: Yale University Mouse Melanoma 2.1 cell line, Yale University Mouse Melanoma cell line
• 分類程式碼代碼: 41106514
• NACRES: NA.81

属性

• product name: YUMM4.1 Mouse Melanoma Cell Line,
• 生物源: mouse
• 品質等級: 100
• 包裝: vial of ≥1X10⁶ cells/vial vials
• 製造商／商標名: Millipore
• 技術: cell culture | mammalian: suitable
• 運輸包裝: liquid nitrogen
• 儲存溫度: −196°C

说明

一般說明

The YUMM4.1 mouse melanoma cell line was derived from a 4-hydroxytamoxifen-induced melanoma tumor in a female C57/Bl/6 mouse into which mutations from the Braf/Pten genetically-engineered mouse model had been introduced via backcrossing. The YUMM4.1 cell line is homozygous negative for Pten and Cdkn2.1?

應用

• Each vial contains > 1X10⁶ viable cells.
• Cells are tested negative for infectious diseases by a Mouse Essential CLEAR panel by Charles River Animal Diagnostic Services.
• Cells are verified to be of mouse origin and negative for inter-species contamination from rat, chinese hamster, Golden Syrian hamster, human and non-human primate (NHP) as assessed by a Contamination CLEAR panel by Charles River Animal Diagnostic Services.
• Cells are negative for mycoplasma contamination.

特點和優勢

The YUMM cell lines recapitulate genetic drivers found in many human melanomas. YUMM4.1 is homozygous negative for Pten and Cdkn2+, and has no activating Braf mutations.

標靶描述

The promise of immune-based therapies in cancer and increasingly successful application of these approaches have emphasized the necessity of immune-competent models to evaluate immunological responses to cancer cells. Immunocompetent genetically-engineered mouse models with distinct genetic drivers of melanoma are essential for identifying potential immunotherapies, but are limited by the need to maintain colonies of multiple genotypes necessary to generate mouse models with appropriate genetic backgrounds.YUMM4.1 cells are syngenic with the immunocompetent C57BL/6 mouse background and retain genetic markers of the Braf/Pten mouse model. Although mutations in Braf V600 are prevalent in melanomas and are targets of specific drugs, first-line treatment of non-Braf mutant melanoma consists of immune checkpoint inhibitors, to which roughly half of patients do not respond. The YUMM4.1 cell line is homozygous negative for Pten and Cdkn2 but has no activating Braf mutations, making this cellular model ideal for investigating the biology of non-Braf-mutant melanomas and potential therapeutics for this difficult subset of cancer.​Mutation: Pten−/− Cdkn2−/−​ . Female.References:1. Meeth K et al. (2016) The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell Melanoma Res 29(5): 590-597.2. Dankort D et al. (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 41(5): 544-552.

儲存和穩定性

Store in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

安全信息

• 儲存類別代碼: 10 - Combustible liquids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable